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Abstract: Combination therapies mediate drug synergy to improve treatment efficacy and
convenience, leading to higher levels of compliance. However, there are challenges with their
manufacturing as well as reduced flexibility in dosing options. This study reports on the design
and characterization of a polypill fabricated through the combination of material jetting and binder
jetting for the treatment of hypertension. The drugs lisinopril and spironolactone were loaded into
hydrophilic hyaluronic acid and hydrophobic poly(ethylene glycol) (PEG) photocurable bioinks,
respectively, and dispensed through a piezoelectric nozzle onto a blank preform tablet composed
of two attachable compartments fabricated via binder jetting 3D printing. The bioinks were
photopolymerized and their mechanical properties were assessed via Instron testing. Scanning
electron microscopy (SEM) was performed to indicate morphological analysis. The polypill
was ensembled and drug release analysis was performed. Droplet formation of bioinks loaded
with hydrophilic and hydrophobic active pharmaceutical ingredients (APIs) was achieved and
subsequently polymerized after a controlled dosage was dispensed onto preform tablet compartments.
High-performance liquid chromatography (HPLC) analysis showed sustained release profiles for
each of the loaded compounds. This study confirms the potential of material jetting in conjunction
with binder jetting techniques (powder-bed 3D printing), for the production of combination therapy
oral dosage forms involving both hydrophilic and hydrophobic drugs.
Keywords: 3D printing; pharmaceutical tablets; poly(ethylene glycol); hyaluronic acid;
photopolymerization; inkjet printing
1. Introduction
Personalized medicine is becoming a reality. For instance, most hearing aids are now custom-fit to
each user’s ear canal [1] and the manufacturing process for InvisalignTM aligners and retainers utilizes
3D printing [2]. Additionally, custom bioresorbable tracheal splints fabricated using laser-based 3D
printing were successfully used to treat children with tracheobronchomalacia [3]. Recently, interest in
applying 3D printing to the manufacturing of pharmaceutical tablets—known as 3D pharming [4]—has
been gaining traction since it can allow for on-demand manufacturing of personalized pharmaceutical
dosage forms [5,6]. It also allows for the creation of dosage forms with increased complexity, including
the manufacturing of oral dosages containing multiple active pharmaceutical ingredients (APIs),
which aim to enhance patient compliance by reducing the number of pills required on a daily basis [7].
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Additionally, several medical conditions utilize combination therapies to improve treatment efficacy,
such as hypertension, HIV infection, depression, type 2 diabetes, and cancer [8–17].
There are several challenges to manufacturing dosage forms containing multiple APIs as well
as dosing constraints that impact treatment efficacy. Currently, a few fixed dose combinations of
varying strength are created for any given combination therapy. However, patients often require
dose adjustments to the extent that a tablet with multiple APIs is not a suitable form factor [18].
Additionally, there are challenges to manufacturing multiple-API dosage forms [19]. For instance,
a common challenge is designing a single dosage form that combines two chemically incompatible
APIs that have to be kept separated. This can result in higher manufacturing costs since a more complex
dosage form has to be produced. Three-dimensional pharming is uniquely positioned to overcome
these obstacles. In fact, techniques such as fused deposition modeling [20] and extrusion printing
at room temperature [21,22] have demonstrated feasibility in the manufacturing of pharmaceutical
tablets with multiple APIs. Material jetting technologies, however, allow for compositional control
at a voxel level, thereby enabling precise dosage control that is tailorable to each individual patient.
Additionally, material can be dispensed at room temperature, which is compatible with thermally
labile APIs.
The focus of this work was to demonstrate that 3D printing and the development of photocurable
formulations can be combined to fabricate pharmaceutical tablets with controlled dosages of both
hydrophilic and hydrophobic APIs, and act as a potential carrier for personalized medicine treatments.
Previously, this lab engineered a hyaluronic acid-based photocurable bioink for the 3D pharming of
hydrophilic compounds via material jetting [23]. Additionally, this lab engineered a poly(ethylene
glycol) diacrylate-based bioink capable of loading hydrophobic drugs [24]. In this paper, both
bioinks are used to manufacture a tablet with multiple APIs used to treat hypertension. Specifically,
the APIs lisinopril and spironolactone were chosen as model drugs for this combination therapy.
Lisinopril, an angiotensin-converting enzyme inhibitor (ACEI) for the treatment of hypertension [25,26],
was chosen due to its hydrophilicity, and spironolactone, a potassium-sparing diuretic for the
treatment of hypertension and congestive heart failure [27], was selected because of its hydrophobicity.
The formulated bioinks were dispensed through a piezoelectric nozzle at room temperature into a
blank preform tablet featuring two compartments, one for each formulation. Compartmentalizing
the preform tablet was required in order to expose each formulation, separately, to the required
light exposure times resulting in optimal mechanical properties and release profiles. The preform
tablet parts were manufactured by binder jetting process, using calcium sulfate powder as the
excipient. The drug-loaded bioinks were subsequently photopolymerized, and the preform tablet parts
were assembled to finalize the pharmaceutical dosage form. This tablet produced a sustained drug
release profile for both APIs and demonstrated that this 3D pharming approach could successfully
fabricate oral combination therapies at room temperature, with quick manufacturing times and
controlled dosages.
2. Materials and Methods
2.1. Hydrophilic Photocurable Bioink Preparation
Hyaluronic acid norbornene (HANB) was synthesized as previously described [23]. Briefly,
hyaluronic acid (HA) (60 kDa·MW) (Genzyme Corporation, Cambridge, MA, USA) was modified
with hydrazide groups through a reaction with adipic acid dihydrazide (ADH) in the presence
of 1-ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride (EDC). The product was dialyzed
for 3 days against deionized water (DI) water (Fisherbrand regenerated cellulose, MWCO
12,000–14,000 Da, Houston, TX, USA), frozen, and lyophilized. On a second reaction, the HA
functionalized with hydrazide groups (HA–ADH) was reacted cis-5-norbornene-endo-2,3-dicarboxylic
anhydride (Sigma–Aldrich, St. Louis, MO, USA), resulting in norbornene-functionalized HA.
The product was dialyzed against DI water for 3 days, filtered, lyophilized, and stored at −20 ◦C.
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Norbornene-functionalized HA was characterized by proton nuclear magnetic resonance spectroscopy
(1H NMR) on a Bruker AV300 broad band FT NMR Spectrometer (Billerica, MA, USA). The degree of
modification obtained was ~50%.
Following its synthesis, HANB was dissolved in PBS and mixed with poly(ethylene glycol) dithiol
(1500 Da, PEGDT) at a crosslinking ratio (ratio of thiol groups to norbornene groups, rratio) of 0.6.
Norbornene-functionalized HA was added at a weight percent (WHANB) of 3%. Eosin Y was added
as a photoinitiator and poly(ethylene glycol) (PEG, 200 Da) was added to optimize the viscosity of
the formulation for droplet formation. Each of these two components constituted 10% v/v of the
bioink. Lisinopril dihydrate (Fisher Scientific, Pittsburgh, PA, USA) was added at a concentration of
40 mg/mL. All chemicals were purchased from Sigma–Aldrich unless otherwise stated.
2.2. Hydrophobic Photocurable Bioink Preparation
The hydrophobic bioink was formulated as previously described [24], with minor modifications.
Briefly, the bioink was composed of 30% poly(ethylene glycol) diacrylate (PEGDA, 250 Da), 50%
PEG200, and 20% ethanol. Eosin Y (1.0 mM) and mPEG-amine (0.05 M) (350 Da, Creative PEG Works,
Chapel Hill, NC, USA) were added as photoinitiator and co-initiator, respectively. Spironolactone was
added at a concentration of 20 mg/mL. All chemicals were purchased from Sigma–Aldrich unless
otherwise stated.
2.3. Bioinks Gelation and Mechanical Properties
The tensile strength of polymerized gels was analyzed to characterize the mechanical properties
of the bioinks. One-mL syringes (BD & Co., Franklin Lakes, NJ, USA), modified by eliminating their
tips, were loaded with 50 µL of bioink. Gels were formed with hydrophilic and hydrophobic bioinks
by exposing them to visible light at an intensity of 120 mW/cm2 for a period of 2 min and 1 min,
respectively. Additionally, the tensile strength of gels with varied drug concentrations was measured to
analyze the impact of drug load on the mechanical properties of the polymerized bioinks. An Instron
(5564 model) was used to measure the failure load of the gels fabricated. The tensile strength (σ) was
calculated through Equation (1), where D is the gel diameter, H is the thickness, and F represents the
failure load [28].
σ =
2F
piDH
(1)
The inverse of the Ohnesorge number (Z value) of the bioinks was calculated to assess the
printability of these solutions through inkjet printing piezoelectric nozzles. Equation (2) defines the Z
value, where a is the radius of the piezoelectric nozzle printing orifice and ρ, γ, and η represent the
density, surface tension, and viscosity of the photocurable formula, respectively [29].
Z =
(aργ)1/2
η
(2)
The surface tension was measured with a tensiometer (Kimble Chase 14,818 Tensiometer,
Cole-Parmer, Vernon Hills, IL, United States) and calculated by using Equation (3), where h is the
distance between menisci of the formulation in the test tube and the one in the capillary tube, r is the
radius of the capillary, ρ is the density of the formulation, and g is the acceleration due to gravity [30].
One mL of each bioink was weighted and the mass obtained was divided by the pre-determined
volume to calculate the density. The viscosity of the bioinks was measured with a rheometer (Discovery
HR-2, TA Instruments, New Castle, DE, USA). A cone and plate geometry (using a 40-mm 2.016◦) was
utilized for the experiment, with a shear rate ranging from 10 to 100 Hz.
γ =
1
2
hrρg (3)
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2.4. Scanning Electron Microscopy (SEM)
The morphology of the gels was observed with a NOVA 230 NanoSEM scanning electron
microscope. Images of lyophilized hydrophilic gels were taken, as well as cross-sectional images of
hydrophobic gels.
2.5. Preform Tablet Fabrication and Characterization
The drug-containing bioinks were directly printed into tablet preforms that were fabricated by
3D printing (ProJet 660; 3D Systems, Inc.; Rock Hill, SC, USA). The printing materials consisted
of calcium sulfate hemihydrate powder (VisiJet PXL Core; 3D Systems, Inc.; Rock Hill, SC, USA),
and a liquid inkjet binder comprised of deionized water containing 5% ethanol and 0.25% Tween 80.
The polypill preform tablet was designed with two separate chambers that could each hold up to 250 µL
of ink and be assembled into a single tablet. The assembled dimensions were kept below the 22-mm
maximum tablet size recommended by the Food and Drug Administration (FDA) [31]. Additionally,
each chamber was independently modified to prevent absorption of the respective drug-containing
bioink into the preform tablet during printing, as previously reported [23]. Briefly, the chamber
holding the hydrophobic formulation was infused with PEG (35 kDa) by submerging the tablet in an
acetone solution containing 15% (w/w) PEG for 30 min at 55 ◦C. Next, the well was brush-coated with
Eudagrit® E100 (Evonik, Essen, Germany) (polymethacrylate copolymer) dissolved in acetone at 20%
(w/w). The chamber holding the hydrophilic formulation was infused with Eudagrit® E100 dissolved
in acetone at 10% (w/w). Surface morphology of the preform tablet was characterized by scanning
electron microscopy (NOVA NanoSEM 230, FEI Co., Hillsboro, OR, USA).
2.6. Drug Release Kinetics
A piezoelectric dispenser with a nozzle diameter of 80 µm (MJ-ABP-01-080, MicroFab, Plano, TX,
USA) was used to assess the droplet formation capability of the engineered bioinks. This dispenser
was controlled with a microdispensing system (MD-E-3000, Microdrop, Norderstedt, Germany).
The dispensing parameters used were 46 V, a 16-µm pulse width, and a frequency of 2000 Hz.
The droplet formation process was captured with an analog camera (JAI CV-S3300), equipped with
a lens (Edmund Optics, Barrington, NJ, USA). A light-emitting diode (LED) was connected to the
microdispensing system in order to control its strobe delay.
Lisinopril-loaded hydrophilic bioink was dispensed in the bottom part of the polypill (250 µL)
and exposed to visible light (120 mW/cm2) for 2 min, to induce gelation of the hydrogel precursor
solution. Spironolactone-loaded hydrophobic bioink was dispensed into the upper piece of the polypill
(125 µL) and exposed to light for 1 min. Following the gelation of the bioinks, the pieces of the polypill
were assembled to finalize the pharmaceutical product.
The tablets were placed into uni-cassettes (Tissue-Tek) and immersed into beakers containing
500 mL of dissolution medium (monobasic potassium phosphate 1.053 mM, pH of 2.5), conditioned at
37 ◦C and stirred at 60 rpm. Aliquots of 1 mL were taken after 0.5, 2, 4, 6, 8, 12, 18, and 24 h. The volume
removed was replenished with fresh dissolution medium conditioned at 37 ◦C. The drug concentration
in each aliquot was measured via HPLC (Waters 2690 with a PDA 996 detector). The wavelength used
to detect the APIs were 220 nm and 240 nm for lisinopril and spironolactone, respectively.
2.7. Statistical Analysis
Statistical analysis was performed with GraphPad Prism software (GraphPad Software, Inc.,
San Diego, CA, USA). Statistical significance was assessed using single factor ANOVA test with a
Tukey post-test and 95% confidence interval.
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3. Results and Discussion
3.1. Bioinks Characterization
Hyaluronic acid is a natural glycosaminoglycan found in connective, neural, and epithelial
tissues [32,33]. The biocompatibility of hyaluronic acid hydrogels has been assessed in tissue
engineering studies, where diverse cell types have been cultured in hydrogels for the formation
of tissues and the study of biological processes [34–36]. Moreover, hyaluronic acid photocurable
formulations can polymerize under quick gelation times (Figure S1). Lisinopril was dissolved in a
hyaluronic acid-based hydrophilic bioink at a concentration of 40 mg/mL. The lisinopril formulation
was dispensed into a modified syringe (50 µL) and exposed to visible light at an intensity of
120 mW/cm2 for 2 min (Figure 1). The storage modulus of the resulting hydrogel was quantified
to assess the mechanical properties of the polymerized bioink, due to its viscoelastic property.
Additionally, hydrogels with different drug concentrations (20 and 10 mg/mL) were polymerized to
study the effect of drug load on the mechanical properties of this hydrophilic material (Figure 2A).
The results indicate that this hydrophilic material has a low storage modulus due to its elevated
water content and the low WHANB (3%) utilized for its fabrication. The elevated water content of the
hydrogel allows for the effective diffusion of the hydrophilic API out of the oral dosage form, given the
dissolution of the preform tablet designed to disintegrate under acidic conditions similar to the ones
found in the stomach. The hydrogels had an average G’ of 1003.86 Pa. Figure 2A indicates that drug
load had no influence in the mechanical properties of the hydrogel, where larger drug concentrations
had no impact over the G’ of the gels. This result is consonant with the G’ data previously shown [23],
where ropinirole-loaded at a concentration of 40 mg/mL had no impact on the mechanical properties
of the gel, compared to hydrogels with no drug. However, a decrease in G’ was noticed on hydrogels
loaded with ropinirole at a concentration of 80 mg/mL. It can be stated that the G’ remains stable
for this lisinopril formulation at concentrations between 0 and 40 mg/mL, the maximum lisinopril
concentration achievable in the hyaluronic acid solution.
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Figure 1. Poly erized drug-loaded bioinks. The upper row shows i ages of the poly erized
hyaluronic acid-based bioink, loaded with lisinopril at a concentration of 40 mg/mL. This bioink
has a WHANB value of 3% and a TL of 2 min. The bottom images show polymerized poly(ethylene
glycol) diacrylate (PEGDA) gels with a WPEGDA value of 30%, a WEtOH value of 20%, and a TL of
1.0 min.
Spironolactone was chosen as the second model drug in this study due to its high hydrophobicity.
The model drug was dissolved in a PEG-based bioink specifically engineered for hydrophobic drugs,
at a concentration of 20 mg/mL. Fifty µL of formulation were pipetted into a modified syringe,
the solution was exposed to light for 1 min (Figure 1), and the tensile strength of the resulting gel
was measured (Figure 2B). Results show an average tensile strength for this material of 176.66 kPa.
The typical tensile strength of pharmaceutical tablets is within the range of 1 and 10 MPa [37].
The G’ obtained for this gel is well below this range, and therefore, this material should be used
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in combination with a preform tablet that provides support and physical stability to the oral dosage
form. Furthermore, the effect of drug concentration on the mechanical properties of the gel was studied
by measuring the tensile strength of gels containing 100, 80, 40, and 20 mg/mL. Figure 2B shows that
drug concentration had no impact on the tensile strength of the material. This contrasts with results
previously demonstrated [24], where a decrease in tensile strength was observed with increasing
naproxen and ibuprofen concentrations. This divergence is due to the lower WPEGDA value used in
this formulation (30%). These results indicate that softer materials consisting of photo-polymerized
bioinks, such as the hyaluronic acid hydrogel, tend to have a steady mechanical stability when exposed
to increasing drug concentrations. Stronger gels can experience substantial differences in mechanical
properties (Figure S2).
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wi h diverse drug concentrations. One-hundred mg/mL was the maximum solubil ty achieved for thi
API. No statistical differ ce was observed between sa ples with varying concentrations.
Scanning electron microscopy imaging was performed on both gels to observe the morphology of
the polymerized structures. Figure 3 shows an irregular surface in both gels with small crevices that
further facilitate the release of drugs, that otherwise diff se out of the gels through their polymerized
c emical structures. The wrinkles observed in t e hydrophilic gel (Figure 3A) are a consequence of the
lyophilized/dehydrated nature of the sample tested.
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3.2. Droplet Formation
To study the droplet formation ability of these bioinks, the inverse of the Ohnesorge number,
denominated as Z value, was calculated (Equation (3)). This dimensionless number considers the
inertia and surface tension forces of a fluid over its viscosity forces to define its droplet formation
ability. The orifice radius of the nozzle used for the inkjet printing of the fluid is also a factor taken
into consideration within this number. Z values between 4 and 14 are considered printable fluids [29].
Values above 14 typically exhibit the formation of satellite droplets, whereas values below four present
strong viscous forces. The viscosity, surface tension, and density of the bioinks was quantified, in order
to determine their Z value. Table 1 shows the results obtained for these parameters at room temperature
and the Z value for the two bioinks utilized in this study. The hydrophilic bioink experienced a higher
viscosity value (9.83 cP), resulting in a lower Z value than the hydrophobic formulation. The later one
had lower viscosity and surface tension parameters (4.88 cP and 31.41 mN/m, respectively), resulting
in a higher Z value of 10.52. However, both formulations fell within the defined range for printable
fluids as depicted in Figures 4 and 5, where the droplet formation sequence of these bioinks can
be observed.
Table 1. Physical properties and Z value of formulated bioinks.
Bioink r P (kg/m3) γ η (mPa·s) Z
Hydrophilic 0.08 1022.27 57.76 9.83 6.99
Hydrophobic 0.08 1048.00 31.41 4.88 10.52
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3.3. Preform Tablet Characterization
The role of the preform tablet was to serve as a vessel for the formulations dispensed prior to their
curing, given that their polymerization occurred after a desir d a ount of formulation was allott d.
There was a need to compart ent lize the tablet for each formulati n added, since each formulation
was cured for different light exposur times to obtain t e desired mechanical properties and drug
release profiles. Calcium sulfate hemihydrate was clinically used in the prepar tion of plaster of Paris,
which is used for casts that immobilize fractures, and is not se i tablet formulati ns [38]. Calcium
sulfate dihy rate, however, has been commonly used i pharmaceutical applic ti s [39], and the
dihydrate is formed wh n hemihydrate is mixed with water [40]. In this study, w ter was used as t
liqui binder during the fabrication of the perform tablets via 3D pri ting (Figure 6). Upon contact with
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the powder, water causes the dissolution of the calcium sulfate hemihydrate and recrystallization of
the dihydrate form [41]. The SEM micrographs (Figure 7A) show that pores exist within the uncoated
preform tablet wall. These pores negatively impacted the performance of tablets during printing of the
bioink. Specifically, the porosity in the preform tablet allowed both the hydrophilic and hydrophobic
bioinks to soak into the preform tablet during printing, which not only weakened the preform tablet,
but also negates the advantages of using 3D printing for pharmaceutical applications, such as control
over drug positioning. To fill the pores, two different coatings were used depending on the ink being
used for printing. For the hydrophilic bioink, the preform tablets were soaked in Eudagrit®E100
(Figure 7B). For the hydrophobic bioink, the preform tablets were first soaked in a high-molecular
weight PEG (35 kDa) solution. High-molecular weight PEG was selected because it is immiscible
with the low-molecular weight PEGDA in the bioink (Figure 7C). Additionally, a thin coating of
Eudagrit®E100 was added to the preform tablet well to further inhibit the absorption of the bioink
during printing. The SEM micrographs show that the polymeric coating fills the pores of the preform
tablet (Figure 7D).
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i re 6. Multi-compartment preform tablet. (A) Side view of the three piec s constituting the preform
tablet. From left t righ , top cap, top compartment, and bottom compart ent. These pi c s were
manufactured by powder-be 3D printing using as binder DI water with 5% e anol and 0.25% Tween
80. The powd r utiliz d for their construction was calcium su fate. Each of the tw wells have a 250 µL
capacity. (B) Front view of the pref rm tablet fabric ted. (C) Comparison between the assembled
version of th preform tablet and commercially available gel c psu s.
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3.4. Polypill Dissolution Test
The hyaluronic acid-based hydrophilic bioink was loaded with lisinopril at a concentration
of 40 mg/mL. Two-hundred-and-fifty µL of this formulation were dispensed into the bottom
compartment of the preform tablet and further exposed to visible light for 2 min, to induce gelation of
the photocurable bioink. Likewise, the PEG-based hydrophobic bioink was loaded with spironolactone
at a concentration of 20 mg/mL. One-hundred-and-twenty-five µL of this formulation were loaded
into the top compartment of the preform tablet and exposed to visible light for a period of 1 min
(Figure 8). Once the bioinks were polymerized, the two compartments were attached, and the small
cap was placed to seal the top compartment, completing the oral dosage form. The tablet was
immersed in a beaker containing 500 mL of dissolution medium, conditioned at 37 ◦C and stirred
at 60 rpm. Aliquots were taken after 0.5, 2, 4, 6, 8, 12, 18, and 24 h of dissolution and their drug
concentration was assessed through HPLC analysis. The results obtained show a dual sustained
release of lisinopril and spironolactone in a period of 24 h (Figure 9). The preform tablet dissolved
almost in its entirety with the exception of the lower part of the top compartment, completely exposing
the gels to the dissolution medium (Figure S3). Lisinopril experienced faster drug release kinetics, when
compared to spironolactone. This result can be explained by the differences in the microarchitecture
and composition of the gels. The hydrophilic formula has over 90% of water content, facilitating the
diffusion of lisinopril, a hydrophilic compound, into the dissolution medium. Moreover, the hydrogel
has a WHANB of only 3%, allowing small molecules to easily diffuse through the polymerize matrix.
The hydrophobic formulation has a higher polymeric content (WPEGDA = 30%) resulting in a mesh
size of ~11 Å [24]. Naproxen and ibuprofen have a hydrodynamic radius of 3.77 Å and 6.80 Å [42],
respectively, and molecular weights of 230.26 Da and 206.29 Da. It can be hypothesized that the
hydrodynamic radius of spironolactone is close to the mesh size of the polymerized hydrophobic gel
(11 Å), since it has a significantly higher molecular weight than naproxen and ibuprofen, model drugs
previously utilized under similar experiment conditions [24]. This would explain the slower release
profile observed with spironolactone, since diffusion of the molecule through the gel matrix would be
impeded. The use of a higher PEGDA molecular weight for the fabrication of the gel could result in
larger mesh sizes and consequently, enhanced drug release kinetics.
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Figure 8. Multi-compartment preform tablet loaded with hydrophilic (bottom) and hydrophobic
(top) bioinks.
The dual release of these APIs for the treatment of hypertension demonstrates the use of inkjet
printing for the fabrication of combination therapies. Moreover, it shows that the therapy could contain
both hydrophilic and hydrophobic compounds. This technology would be especially applicable
towards drugs that achieve their pharmacological effect at low dosages and could be targeted towards
Polymers 2018, 10, 1372 10 of 12
the development of oral dosage forms for children who require small dosages not always commercially
available. Moreover, children experience drastic changes in metabolism that affect the dosage needed
to achieve a given target pharmacological effect.
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